Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Ephedrine Sulfate Injection USP, 50 mg/mL single-dose vials, the company announced through an exchange filing.
Ephedrine Sulfate Injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara (India).
Ephedrine Sulfate Injection USP, 50 mg/mL had annual sales of USD 52 mn in the United States.
The group now has 368 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.
Indian Astronaut Shubhanshu Shukla & 3 Other Crew Members Of Axiom-4 To Start Their Return Journey To Earth Today (VIDEO)
Pune: FDA Suspends Goodluck Cafe's Licence After Glass Shard Found In Bun Maska (VIDEO)
Stuntman SM Raju Dies As Car Stunt Goes Horribly Wrong On Sets Of PA Ranjith's Next Film, Shocking Video Surfaces
Bastille Day 2025: Why France Celebrates Its National Day On July 14?
